Skip to main content
SpringerLink
Log in

Menopause and Bone Metabolism

  • Living reference work entry
  • First Online:
Female Reproductive Dysfunction

Part of the book series: Endocrinology ((ENDOCR))

  • 223 Accesses

Abstract

The hormonal changes that take place at menopause are the most important reason why women are at greater risk of osteoporosis than men.

Fragility fractures osteoporosis related are a relevant cause of disability and excess mortality in postmenopausal women.

General measures such as calcium and vitamin D supplementation or physical exercise could be very useful for prevention of fragility fractures.

The use of registered drugs is recommended when the health benefits overcome the risks. The FRAX® algorithm is a scientifically validated risk assessment tool that improves identification of patients at high risk of fracture.

Antiresorptive agents are the predominant therapeutic category for preventing fractures, and bisphosphonates are still the most commonly used. However, new and more effective therapies are nowadays available for prevention and treatment of bone loss.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Similar content being viewed by others

References

  • Abrahamsen B, et al. Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. J Bone Miner Res. 2009a;24:1095–102.

    Article  CAS  PubMed  Google Scholar 

  • Abrahamsen B, et al. Atrial fibrillation in fracture patients treated with oral bisphosphonates. J Intern Med. 2009b;265:581–92.

    Article  CAS  PubMed  Google Scholar 

  • Baim S, et al. Assessing the clinical utility of serum CTX in postmenopausal osteoporosis and its use in predicting risk of osteonecrosis of the jaw. J Bone Miner Res. 2009;24:561–74.

    Article  CAS  PubMed  Google Scholar 

  • Barrett-Connor E, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med. 2006;355:125–37.

    Article  CAS  PubMed  Google Scholar 

  • Black DM, et al. One year of alendronate after one year of parathyroid hormone (1–84) for osteoporosis. N Engl J Med. 2005;353:555–65.

    Article  CAS  PubMed  Google Scholar 

  • Black DM, et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA. 2006;296:2927–38.

    Article  CAS  PubMed  Google Scholar 

  • Black DM, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356:1809–22.

    Article  CAS  PubMed  Google Scholar 

  • Bone HG, et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J Clin Endocrinol Metab. 2008;93:2149–57.

    Article  CAS  PubMed  Google Scholar 

  • Bunch TJ, et al. Relation of bisphosphonate therapies and risk of developing atrial fibrillation. Am J Cardiol. 2009;103:824–8.

    Article  CAS  PubMed  Google Scholar 

  • Burghardt AJ, et al. A longitudinal HR-pQCT study of alendronate treatment in postmenopausal women witeh low bone density: relations among density, cortical and trabecular microarchitecture, biomechanics, and bone turnover. J Bone Miner Res. 2010;25:2558–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Chapurlat RD, et al. Microcrack frequency and bone remodeling in postmenopausal osteoporotic women on long-term bisphosphonates: a bone biopsy study. J Bone Miner Res. 2007;22:1502–9.

    Article  CAS  PubMed  Google Scholar 

  • Collins P, et al. Effects of the selective estrogen receptor modulator raloxifene on coronary outcomes in the Raloxifene Use for The Heart trial: results of subgroup analyses by age and other factors. Circulation. 2009;119:922–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Cosman F, et al. Daily and cyclic parathyroid hormone in women receiving alendronate. N Engl J Med. 2005;353:566–75.

    Article  CAS  PubMed  Google Scholar 

  • Cosman F, et al. Effects of intravenous zoledronic acid plus subcutaneous teriparatide (rhPTH(1–34)) in postmenopausal osteoporosis. J Bone Miner Res. 2011;26:503–11.

    Article  CAS  PubMed  Google Scholar 

  • Cosman F, et al. Clinician’s guide to prevention and treatment of osteoporosis. Osteoporos Int. 2014;25(10):2359–2381.

    Google Scholar 

  • Cosman F, et al. Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med. 2016;375:1532–43.

    Article  CAS  PubMed  Google Scholar 

  • Cosman F, et al. Treatment sequence matters: anabolic and antiresorptive therapy for osteoporosis. J Bone Miner Res. 2017;32:198–202.

    Article  CAS  PubMed  Google Scholar 

  • Cosman F, et al. FRAME study: the foundation effect of building Bone with 1 year of Romosozumab leads to continued lower fracture risk after transition to Denosumab. J Bone Miner Res. 2018;33:1219–26.

    Article  CAS  PubMed  Google Scholar 

  • Cranney A, et al. Ibandronate for the prevention of nonvertebral fractures: a pooled analysis of individual patient data. Osteoporos Int. 2009;20:291–7.

    Article  CAS  PubMed  Google Scholar 

  • Cummings SR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361:756–65.

    Article  CAS  PubMed  Google Scholar 

  • Curtis JR, et al. Risk of hip fracture after bisphosphonate discontinuation: implications for a drug holiday. Osteoporos Int. 2008;19:1613–20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Ensrud KE, et al. Effects of raloxifene on fracture risk in postmenopausal women: the Raloxifene Use for The Heart trial. J Bone Miner Res. 2008;23:112–20.

    Article  CAS  PubMed  Google Scholar 

  • EPOS Group, et al. Incidence of limb fracture across Europe: results from the European Prospective Osteoporosis Study (EPOS). Osteoporosis Int. 2002;13:565–71.

    Article  Google Scholar 

  • Eriksen EF, et al. Antifracture efficacy and reduction of mortality in relation to timing of the first dose of zoledronic acid after hip fracture. J Bone Miner Res. 2009;24:1308–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Finkelstein JS, et al. Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis. J Clin Endocrinol Metab. 2010;95:1838–45.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Genant H, et al. Noninvasive assessment of bone mineral and structure: state of the art. J Bone Miner Res. 1996;11(6):707–30.

    Google Scholar 

  • Gennari L, et al. Osteoporosis in men. Endocrinol Metab Clin North Am. 2007;36:399–419.

    Article  CAS  PubMed  Google Scholar 

  • Haentjens P, On behalf of the Network on Male Osteoporosis in Europe (NEMO), et al. Evidence from data searches and life-table analyses for gender-related differences in absolute risk of hip fracture after Colles’ or spine fracture: Colles’ fracture as an early and sensitive marker of skeletal fragility in white men. J Bone Miner Res. 2004;19:1933–44.

    Article  PubMed  Google Scholar 

  • Harris ST, et al. Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies. Curr Med Res Opin. 2008;24:237–45.

    Article  CAS  PubMed  Google Scholar 

  • Hodsman AB, et al. Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev. 2005;26:688–703.

    Article  CAS  PubMed  Google Scholar 

  • Hoff AO, et al. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res. 2008;23:826–36.

    Article  CAS  PubMed  Google Scholar 

  • Johansson H, et al. Imminent risk of fracture after fracture. Osteoporos Int. 2017;28:775–80.

    Article  CAS  PubMed  Google Scholar 

  • Johnell O, et al. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporosis Int. 2006;17(12):1726–33. Epub 2006 Sep 16.

    Google Scholar 

  • Kanis JA, et al. A meta-analysis of previous fracture and subsequent fracture risk. Bone. 2004;35(2):375–82.

    Article  CAS  PubMed  Google Scholar 

  • Kanis JA, et al. Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX. Bone. 2009;44:1049–54.

    Article  CAS  PubMed  Google Scholar 

  • Kelley GA, et al. Exercise and bone mineral density in premenopausal women: a meta-analysis of randomized controlled trials. Int J Endocrinol. 2013;2013:741639.

    PubMed  PubMed Central  Google Scholar 

  • Kenneth G, et al. Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med. 2017;377:1417–27.

    Article  Google Scholar 

  • Lee S, et al. Efficacy, side effects and route of administration are more important than frequency of dosing of anti-osteoporosis treatments in determining patient adherence: a critical review of published articles from 1970 to 2009. Osteoporos Int. 2011;22:741–53.

    Article  CAS  PubMed  Google Scholar 

  • Leeming DJ, et al. An update on biomarkers of bone turnover and their utility in biochemical research and clinical practice. Eur J Clin Pharmacol. 2006;62:781–92.

    Article  CAS  PubMed  Google Scholar 

  • Lips P, et al. Vitamin D physiology. Prog Biophys Mol Biol. 2006;92(1):4–8.

    Article  CAS  PubMed  Google Scholar 

  • Lyles KW, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007;357:1799–809.

    Article  CAS  PubMed  Google Scholar 

  • Magopoulos C, et al. Osteonecrosis of the jaws due to bisphosphonate use. A review of 60 cases and treatment proposals. Am J Otolaryngol. 2007;28:158–63.

    Article  CAS  PubMed  Google Scholar 

  • Mbalaviele G, et al. Beta-catenin and BMP-2 synergize to promote osteoblast differentiation and new bone formation. J Cell Biochem. 2005;94:403–18.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • McClung MR, et al. Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med. 2014;370:412–20.

    Article  CAS  PubMed  Google Scholar 

  • Melton LJ III, et al. Epidemiology of vertebral fractures: implications for vertebral augmentation. Acad Ther. 2006;13:538–45.

    Google Scholar 

  • Meunier PJ, et al. Effects of long-term strontium ranelate treatment on vertebral fracture risk in postmenopausal women with osteoporosis. Osteoporos Int. 2009;20:1663–73.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Miller PD, et al. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and re- starting of therapy: a randomized blinded phase2 clinical trial. Bone. 2008;43:222–9.

    Article  CAS  PubMed  Google Scholar 

  • Miller PD, et al. Denosumab or zoledronic acid in postmenopausal women with osteoporosis previously treated with oral bisphosphonates. J Clin Endocrinol Metab. 2016;101:3163.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Moreira LDF, et al. Physical exercise and osteoporosis: effects of different types of exercises on bone and physical function of postmenopausal women. Arq Bras Endocrinol Metabol. 2014;58(5):514–22.

    Article  PubMed  Google Scholar 

  • Mosca L, et al. Effect of raloxifene on stroke and venous thromboembolism according to subgroups in postmenopausal women at increased risk of coronary heart disease. Stroke. 2009;40:147–55.

    Article  CAS  PubMed  Google Scholar 

  • Ominsky MS, et al. Tissue-level mechanisms responsible for the increase in bone formation and bone volume by sclerostin antibody. J Bone Miner Res. 2014;29:1424–30.

    Article  CAS  PubMed  Google Scholar 

  • Padhi D, et al. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res. 2011;26:19–26.

    Article  CAS  PubMed  Google Scholar 

  • Papapoulos SE, et al. Meta-analysis of the efficacy of alendronate for the prevention of hip fractures in postmenopausal women. Osteoporos Int. 2005;16:468–74.

    Article  CAS  PubMed  Google Scholar 

  • Pilbeam C, et al. Prostaglandins and bone metabolism. In: Bilezikian JP, Raisz LG, Rodan GA, editors. Principles of bone biology. San Diego: Academic; 2002. p. 979–94.

    Chapter  Google Scholar 

  • Poole KE, et al. Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J. 2005;19:1842–4.

    Article  CAS  PubMed  Google Scholar 

  • Prince R, et al. Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment. J Bone Miner Res. 2005;20:1507–13.

    Article  CAS  PubMed  Google Scholar 

  • Reginster JY, Rabenda V, et al. Adherence to anti-osteoporotic treatment: does it really matter? Future Rheumatol. 2006;1(1):37–40.

    Article  CAS  Google Scholar 

  • Reid DM, et al. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet. 2009;373:1253–63.

    Article  CAS  PubMed  Google Scholar 

  • Saag KG, et al. Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med. 2017;377:1417–27.

    Article  CAS  PubMed  Google Scholar 

  • Sambrook P, et al. Lancet. 2006;367:2010–8.

    Article  CAS  PubMed  Google Scholar 

  • Seeman E, et al. Bone quality – the material and structural basis of bone strength and fragility. N Engl J Med. 2006;354(21):2250–61.

    Article  CAS  PubMed  Google Scholar 

  • Silverman SL, et al. Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial. J Bone Miner Res. 2008;23:1923–34.

    Article  CAS  PubMed  Google Scholar 

  • Silverman SL, et al. Osteonecrosis of the jaw and the role of bisphosphonates: a critical review. Am J Med. 2009;122(2 Suppl):S33–45.

    Article  CAS  PubMed  Google Scholar 

  • Silverman SL, et al. Oral bisphosphonate compliance and persistence: a matter of choice? Osteoporos Int. 2011;22:21–6.

    Article  CAS  PubMed  Google Scholar 

  • Sorensen HT, et al. Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case-control study. BMJ. 2008;336:813–6.

    Article  PubMed  PubMed Central  Google Scholar 

  • Tsai JN, et al. Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomized trial. Lancet. 2013;382:50–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Tsai JN, et al. Comparative effects of teriparatide, denosumab, and combination therapy on peripheral compartmental bone density, microarchitecture, and estimated strength, the DATA-HRpQCT Study. J Bone Miner Res. 2015;30(1):39–45.

    Article  CAS  PubMed  Google Scholar 

  • van Bezooijen RL, et al. Wnt but not BMP signaling is involved in the inhibitory action of sclerostin on BMP-stimulated bone formation. J Bone Miner Res. 2007;22:19–28.

    Article  PubMed  Google Scholar 

  • Weycker D, et al. Compliance with drug therapy for postmenopausal osteoporosis. Osteoporosis Int. 2006;17:1645.

    Article  CAS  Google Scholar 

  • Wijenayaka AR, et al. Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway. PLoS One. 2011;6:25900.

    Article  CAS  Google Scholar 

  • Wilk A, et al. Post-fracture pharmacotherapy for women with osteoporotic fracture: analysis of a managed care population in the USA. Osteoporos Int. 2014;25:2777–86.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Yarom N, et al. Osteonecrosis of the jaw induced by orally administered bisphosphonates: incidence, clinical features, predisposing factors and treatment outcome. Osteoporos Int. 2007;18:1363–70.

    Article  CAS  PubMed  Google Scholar 

  • Zallone A, et al. Direct and indirect estrogen actions on osteoblasts and osteoclasts. Ann N Y Acad Sci. 2006;1068:173–9.

    Article  CAS  PubMed  Google Scholar 

  • Zanchetta JR, et al. Effects of teriparatide (recombinant human parathyroid hormone (1–34)) on cortical bone in postmenopausal women with osteoporosis. J Bone Miner Res. 2003;18:539–43.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. FirmoLab Fondazione F.I.R.M.O, Florence, Italy

    ML. Brandi

  2. University of Florence, Metabolic Bone Diseases Unit, University Hospital of Florence, Florence, Italy

    ML. Brandi & L. Di Medio

Authors
  1. ML. Brandi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L. Di Medio
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to ML. Brandi .

Editor information

Editors and Affiliations

  1. Deaprtment of Obstatrics and Gynecology, Azienda Ospedaliero-Universitaria Caregg, Firenze, Italy

    Felice Petraglia

  2. Obstetrics and Gynecology, Utrecht University, Utrecht, Utrecht, The Netherlands

    Bart CJM Fauser

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Brandi, M., Di Medio, L. (2020). Menopause and Bone Metabolism. In: Petraglia, F., Fauser, B. (eds) Female Reproductive Dysfunction . Endocrinology. Springer, Cham. https://doi.org/10.1007/978-3-030-03594-5_19-1

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-03594-5_19-1

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-03594-5

  • Online ISBN: 978-3-030-03594-5

  • eBook Packages: Springer Reference MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation